Poly(lactic-co-glycolic acid) microsphere production based on quality by design: a review
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Poly(lactic-co-glycolic acid) (PLGA) has garnered increasing attention as a candidate drug delivery polymer owing to its favorable properties, including its excellent biocompatibility, biodegradability, non-toxicity, non-immunogenicity, and mechanical strength. PLAG are specifically used as microspheres for the sustained/controlled and targeted delivery of hydrophilic or hydrophobic drugs, as well as biological therapeutic macromolecules, including peptide and protein drugs. PLGAs with different molecular weights, lactic acid (LA)/glycolic acid (GA) ratios, and end groups exhibit unique release characteristics, which is beneficial for obtaining diverse therapeutic effects. This review aims to analyze the composition of PLGA microspheres, and understand the manufacturing process involved in their production, from a quality by design perspective. Additionally, the key factors affecting PLGA microsphere development are explored as well as the principles involved in the synthesis and degradation of PLGA and its interaction with active drugs. Further, the effects elicited by microcosmic conditions on PLGA macroscopic properties, are analyzed. These conditions include variations in the organic phase (organic solvent, PLGA, and drug concentration), continuous phase (emulsifying ability), emulsifying stage (organic phase and continuous phase interaction, homogenization parameters), and solidification process (relationship between solvent volatilization rate and curing conditions). The challenges in achieving consistency between batches during manufacturing are addressed, and continuous production is discussed as a potential solution. Finally, potential critical quality attributes are introduced, which may facilitate the optimization of process parameters.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Farah, S., Anderson, D. G., & Langer, R. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.012 · Cited by 3,443
Jain, R. A. (2000) · Biomaterials · doi:10.1016/s0142-9612(00)00115-0 · Cited by 2,214
An Overview of Poly(lactic-co-glycolic) Acid (PLGA)-Based Biomaterials for Bone Tissue Engineering
Gentile, P., Chiono, V., Carmagnola, I., & Hatton, P. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15033640 · Cited by 1,593
Challenges in Development of Nanoparticle-Based Therapeutics
Desai, N. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9339-4 · Cited by 1,173 · cited 1×
“In this respect, continuous processes are beneficial, as they allow the termination of production when the target quantities have been produced, without altering the process parameters based on the production scale (Desai, 2012; Ranjan et al., 2012; Ye & Squillante, 2013; Paliwal et al., 2014).”
MethodFreitas, S., Merkle, H. P., & Gander, B. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.10.015 · Cited by 923
Effect of acidic pH on PLGA microsphere degradation and release
Zolnik, B. S., & Burgess, D. J. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.034 · Cited by 560 · cited 2×
“The hydrolyzed product has a high local concentration of hydrolysates in the structure, which autocatalyze internal degradation and polymer erosion (Fu et al., 2000; Zolnik & Burgess, 2007; Sch€adlich et al., 2014).”
BackgroundMAO, S., XU, J., CAI, C., GERMERSHAUS, O., SCHAPER, A., & KISSEL, T. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.10.036 · Cited by 283
Chemical degradation of peptides and proteins in PLGA: A review of reactions and mechanisms
Houchin, M. L., & Topp, E. M. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21176 · Cited by 277
Phase inversion dynamics of PLGA solutions related to drug delivery
Graham, P. D., Brodbeck, K. J., & McHugh, A. J. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(98)00158-8 · Cited by 222 · cited 1×
“For instance, a lower proportion of lactide than galactide in the copolymer may decrease the Tg (Graham et al., 1999), which is an indicator of the chain structure rigidity and is generally above 37 C.”
BackgroundEffect of drug type on the degradation rate of PLGA matrices
SIEGEL, S., KAHN, J., METZGER, K., WINEY, K., WERNER, K., & DAN, N. (2006) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2006.06.009 · Cited by 208
Cited by
Liu, S., Yu, J.-M., Gan, Y.-C., Qiu, X.-Z., Gao, Z.-C., Wang, H., Chen, S.-X., Xiong, Y., Liu, G.-H., Lin, S.-E., et al. (2023) · Military Medical Research · doi:10.1186/s40779-023-00448-w · Cited by 357
Recent Applications of PLGA in Drug Delivery Systems
Yang, J., Zeng, H., Luo, Y., Chen, Y., Wang, M., Wu, C., & Hu, P. (2024) · Polymers · doi:10.3390/polym16182606 · Cited by 268
Nanomaterials: Breaking through the bottleneck of tumor immunotherapy
Kang, Y., & Li, S. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123159 · Cited by 61
PLGA-Based Co-Delivery Nanoformulations: Overview, Strategies, and Recent Advances
Stevanović, M. M., Qian, K., Huang, L., & Vukomanović, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121613 · Cited by 42
“For instance, PLGA microspheres have been utilised in LAI formulations for leuprolide acetate, a treatment for prostate cancer and endometriosis, allowing for extended dosing intervals and improved patient compliance [138,139].”
Influential
Metadata
- Authors
- Hua, Y., Su, Y., Zhang, H., Liu, N., Wang, Z., Gao, X., Gao, J., & Zheng, A.
- Venue
- Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2021-01
- Volume
- 28
- Issue
- 1
- Pages
- 1342-1355
- ISSN
- 1071-7544 (ISSN-L)
- 1521-0464
- OpenAlex
- W3175766113
- Cited by
- 175
- References
- 16
- FWCI
- 7.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Poly(lactic-co-glycolic acid) microsphere production based on quality by design: a review. https://app.cochat.ai/papers/10.1080/10717544.2021.1943056
- The paper
- Hua, Y., Su, Y., Zhang, H., Liu, N., Wang, Z., Gao, X., Gao, J., & Zheng, A. (2021). Poly(lactic-co-glycolic acid) microsphere production based on quality by design: a review. Drug Delivery. https://doi.org/10.1080/10717544.2021.1943056
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.